Xilio Therapeutics, Inc.: Logos Global Management LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Logos Global Management LP disclosed a stake exceeding 5% in Xilio Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000935836-26-000612). The filing signals that the investment firm has crossed the key 5% beneficial ownership threshold, making it a reportable major shareholder in the clinical-stage biotech. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify Logos's position size and intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Logos Global Management LP, Xilio Therapeutics, Inc.